Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection

J Cyst Fibros. 2022 Sep;21(5):821-829. doi: 10.1016/j.jcf.2022.01.003. Epub 2022 Jan 24.

Abstract

OligoG has previously shown potentiation of aztreonam against Burkholderia cepacia complex (Bcc) through biofilm disruption. A randomized, double-blind, placebo-controlled cross-over design was used to evaluate safety and efficacy of inhaled OligoG as a therapy for Bcc-infected CF patients taking aztreonam. Subjects received OligoG (1050 mg daily) or matching placebo for 28-days. Of 14 subjects completing the study, 8 showed a mean decrease in total bacterial CFU's (0.82 log10) after OligoG treatment. There was a reduction in mean Bcc CFU's (2.19 log10) after OligoG treatment but this was not statistically significant. Rheology analysis showed improvements in phase-angle after OligoG, but there was no statistically significant improvement in lung function parameters. Six out of 12 QoL summary scores showed relative improvement after OligoG treatment compared to placebo. There was a favourable safety profile for OligoG. Potential for reducing Bcc warrants further investigation of OligoG for the treatment of infection in CF.

Trial registration: ClinicalTrials.gov NCT02453789.

Keywords: Alginate oligosaccharide; Burkholderia cepacia complex (Bcc) bacteria; Cystic fibrosis; FEV1; OligoG.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alginates
  • Aztreonam
  • Burkholderia Infections* / diagnosis
  • Burkholderia Infections* / drug therapy
  • Burkholderia Infections* / microbiology
  • Burkholderia cepacia complex*
  • Cystic Fibrosis* / complications
  • Cystic Fibrosis* / drug therapy
  • Cystic Fibrosis* / microbiology
  • Humans
  • Lung
  • Oligosaccharides
  • Quality of Life

Substances

  • Alginates
  • Oligosaccharides
  • Aztreonam

Associated data

  • ClinicalTrials.gov/NCT02453789